SION
Sionna Therapeutics, Inc.
$5.29
-0.23
(-4.17%)
Mkt Cap
238.85M
Volume
1,908,334
52W Range
4.01-54.97
Sector
Healthcare
Beta
1.32
EPS (TTM)
-2.18 USD
P/E Ratio
-21.88
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Net Income | (75.27M) | (61.69M) | (47.26M) | (40.24M) |
| EPS | -1.88 | -1.40 | -1.07 | -0.91 |
| Free Cash Flow | (66.67M) | (52.81M) | (44.81M) | (37.94M) |
| FCF / Share | -1.67 | -1.20 | -1.02 | -0.86 |
| Operating CF | (66.30M) | (52.79M) | (43.70M) | (36.07M) |
| Total Assets | 325.95M | 185.75M | 51.95M | 87.37M |
| Total Debt | 8.68M | 9.75M | 10.48M | 0 |
| Cash & Equiv | 58.45M | 37.79M | 38.52M | 54.84M |
| Book Value | 306.83M | (163.71M) | (114.88M) | (69.92M) |
| Return on Equity | -0.25 | N/A | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (29.89M) | (26.78M) | (20.44M) | (20.28M) | (18.07M) | (16.48M) | (15.85M) | (25.44M) | (8.55M) | (11.85M) | (11.88M) |
| EPS | -0.66 | -0.60 | -0.46 | -0.46 | -0.41 | -0.37 | -0.36 | -0.58 | -0.19 | -0.27 | -0.27 |
| Free Cash Flow | (44.06M) | (21.84M) | (16.83M) | (15.32M) | (18.15M) | (16.37M) | (11.81M) | (17.69M) | (10.14M) | (13.18M) | (7.57M) |
| FCF / Share | -0.98 | -0.49 | -0.42 | -0.34 | -0.41 | -0.37 | -0.27 | -0.40 | -0.23 | -0.30 | -0.17 |
| Operating CF | (44.06M) | (21.84M) | (16.63M) | (15.23M) | (18.15M) | (16.29M) | (11.78M) | (17.69M) | (10.14M) | (13.18M) | (7.45M) |
| Total Assets | 283.25M | 305.04M | 325.95M | 339.27M | 352.05M | 369.67M | 185.75M | 197.26M | N/A | N/A | 51.95M |
| Total Debt | 8.07M | 8.38M | 8.68M | 8.97M | 9.24M | 9.50M | 9.75M | 9.99M | N/A | N/A | 10.48M |
| Cash & Equiv | 63.32M | 63.32M | 58.45M | 50.83M | 40.98M | 82.69M | 37.79M | 35.75M | N/A | N/A | 38.52M |
| Book Value | 265.77M | 288.21M | 306.83M | 321.67M | 336.43M | 351.77M | (163.71M) | (148.55M) | N/A | N/A | (114.88M) |
| Return on Equity | -0.11 | -0.09 | -0.07 | -0.06 | -0.05 | -0.05 | N/A | N/A | N/A | N/A | N/A |
SION News
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced -- Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Sionna Therapeutics, Inc. (SION) Shareholders Who Lost Money -- Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Sionna Therapeutics (SION)
SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law
SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law
SION INVESTOR ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
SION Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Sionna Therapeutics (SION)